[ Special series on Colorectal Cancer ]
doi: 10.1186/s40880-015-0061-3
Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer
Zhi-Qiang Wang, Dong-Sheng Zhang, Nong Xu, De-Yun Luo, Yan-Hong Deng, Feng-Hua Wang, Hui-Yan Luo, Miao-Zhen Qiu, Yu-Hong Li and Rui-Hua Xu
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine; Department of Medical Oncology, Sun Yat-sen University Cancer Center
[Abstract]
Background
Fluoropyrimidine and oxaliplatin are widely used for patients with colorectal cancer. This phase II study was conducted to evaluate the efficacy and safety of the combination of S-1, oxaliplatin, and leucovorin (SOL) in the treatment of Chinese patients with metastatic colorectal cancer (mCRC).
Methods
Eligible patients with untreated mCRC from four hospitals in China received intravenous oxaliplatin (85 mg/m2) on day 1, oral S-1 twice daily (80–120 mg per day) on day 1–7, and leucovorin twice daily (50 mg per day) simultaneously with S-1, every 2 weeks.
Results and discussion
Forty patients were enrolled in our study. In total, 296 cycles of SOL were administered. The overall response rate was 50.0%. At a median follow-up of 27 months, progression-free survival and overall survival were 7.0 months (95% confidence interval [CI] 6.0–10.6 months) and 22.2 months (95% CI 15.1–29.3 months), respectively. The most common grade 3/4 non-hematological adverse events were diarrhea (n = 8, 20.0%), nausea (n = 3, 7.5%), and vomiting (n = 3, 7.5%). The most common grade 3/4 hematological toxicities were thrombocytopenia (n = 3, 7.5%), neutropenia (n = 1, 2.5%), and abnormal alanine transaminase/aspartate transaminase levels (n = 1, 2.5%). There was one treatment-related death.
Conclusions
The data indicate that the SOL regimen is effective and moderately tolerated in Chinese patients with mCRC.
Background
Fluoropyrimidine and oxaliplatin are widely used for patients with colorectal cancer. This phase II study was conducted to evaluate the efficacy and safety of the combination of S-1, oxaliplatin, and leucovorin (SOL) in the treatment of Chinese patients with metastatic colorectal cancer (mCRC).
Methods
Eligible patients with untreated mCRC from four hospitals in China received intravenous oxaliplatin (85 mg/m2) on day 1, oral S-1 twice daily (80–120 mg per day) on day 1–7, and leucovorin twice daily (50 mg per day) simultaneously with S-1, every 2 weeks.
Results and discussion
Forty patients were enrolled in our study. In total, 296 cycles of SOL were administered. The overall response rate was 50.0%. At a median follow-up of 27 months, progression-free survival and overall survival were 7.0 months (95% confidence interval [CI] 6.0–10.6 months) and 22.2 months (95% CI 15.1–29.3 months), respectively. The most common grade 3/4 non-hematological adverse events were diarrhea (n = 8, 20.0%), nausea (n = 3, 7.5%), and vomiting (n = 3, 7.5%). The most common grade 3/4 hematological toxicities were thrombocytopenia (n = 3, 7.5%), neutropenia (n = 1, 2.5%), and abnormal alanine transaminase/aspartate transaminase levels (n = 1, 2.5%). There was one treatment-related death.
Conclusions
The data indicate that the SOL regimen is effective and moderately tolerated in Chinese patients with mCRC.
Chinese Journal of Cancer 2016, Volume: 35, Issue 3
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)
[Google Scholar]
[ More articles of the special series on Colorectal Cancer ]
Cite this article
Zhi-Qiang Wang, Dong-Sheng Zhang, Nong Xu, De-Yun Luo, Yan-Hong Deng, Feng-Hua Wang, Hui-Yan Luo, Miao-Zhen Qiu, Yu-Hong Li and Rui-Hua Xu. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer. Chin J Cancer. 2016, 35:8. doi:10.1186/s40880-015-0061-3
Export citations
EndNote
[ Html full-text / Citation export] (BioMed Central)
[Google Scholar]
[ More articles of the special series on Colorectal Cancer ]
Cite this article
Zhi-Qiang Wang, Dong-Sheng Zhang, Nong Xu, De-Yun Luo, Yan-Hong Deng, Feng-Hua Wang, Hui-Yan Luo, Miao-Zhen Qiu, Yu-Hong Li and Rui-Hua Xu. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer. Chin J Cancer. 2016, 35:8. doi:10.1186/s40880-015-0061-3
Export citations
EndNote
SHARE THIS ARTICLE
Comments: